AI Article Synopsis
- Desmoplakin (DSP) is a crucial protein in desmosomes that connects cells, and mutations in its NH-terminal region are linked to heart disease and skin issues.
- A specific mutation in this region can expose a calpain target site that contributes to the disease, making DSP levels decrease.
- Researchers found that adding a mutation at position 518 (L518Y) stabilizes the protein, partially blocking the calpain site and restoring DSP levels, offering potential new treatment strategies for DSP-related disorders.
Article Abstract
Desmoplakin (DSP) is a large (~260 kDa) protein found in the desmosome, a subcellular complex that links the cytoskeleton of one cell to its neighbor. A mutation 'hot-spot' within the NH-terminal third of the DSP protein (specifically, residues 299-515) is associated with both cardiomyopathies and skin defects. In select DSP variants, disease is linked specifically to the uncovering of a previously-occluded calpain target site (residues 447-451). Here, we partially stabilize these calpain-sensitive DSP clinical variants through the addition of a secondary single point mutation-tyrosine for leucine at amino acid position 518 (L518Y). Molecular dynamic (MD) simulations and enzymatic assays reveal that this stabilizing mutation partially blocks access to the calpain target site, resulting in restored DSP protein levels. This 'molecular band-aid' provides a novel way to maintain DSP protein levels, which may lead to new strategies for treating this subset of DSP-related disorders.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151963 | PMC |
| http://dx.doi.org/10.3390/jpm11050401 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!